Buy Insys Therapeutics Before Medical Marijuana Reaches A Tipping Point
Medical marijuana is already approved in over half of the U.S. and 5 more states will be voting on it in 2016. Todd Hagopian says we will soon see a tipping point in which medical marijuana companies like Insys Therapeutics (INSY) will be transformed from fringe enterprises trading at a discount into mainstream biotech companies with premium valuations.
Todd started his Biotech fund at Marketocracy in March, 2011. His returns have averaged 28.84% since then, which compares nicely to the S&P 500’s 8.89% return over the same period. Over the last five and three year periods, he did better than the top U.S. Equity fund manager. Before taking anyone’s investment advice, you should always check out their track record. Click here to see Todd’s.
Ken Kam: What does the market expect from Insys Therapeutics?
Todd Hagopian: Four analysts follow the stock, at the moment. Three of them rate it a strong buy, and one...
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
Follow us on Instagram
Connect with us on Linkedin